Sun Pharmaceutical Industries Limited Launches Semaglutide Injection in Brazil
Sun Pharmaceutical Industries Limited (NSE: SUNPHARMA, BSE: 524715)
Date: 29 July 2026
Sun Pharmaceutical Industries Limited (Sun Pharma) announced that it has received regulatory approval from Brazil’s health authority, ANVISA, to manufacture and market semaglutide injection in Brazil for the treatment of adults with inadequately controlled type 2 diabetes mellitus.
Key Highlights
- Regulatory approval: ANVISA has cleared Sun Pharma’s semaglutide injectable for the Brazilian market.
- Product format: Pre‑filled, multi‑dose injectable pen available in two strengths:
- 2 mg/1.5 mL
- 4 mg/3 mL
- Designed for flexible, once‑weekly dosing.
- Launch timeline: Commercial launch is planned within the next few days.
- Partner: Sun Pharma will commercialise the product in Brazil in partnership with Hypera Pharma, a leading local pharmaceutical company.
- Market opportunity: The Brazilian semaglutide injectable market is estimated at ≈ USD 413 million (IQVIA, MAT June 2026).
Executive Comments
-
Aalok Shanghvi, COO, Sun Pharma:
“The approval of semaglutide in Brazil expands access to an evidence‑based treatment option for people living with inadequately controlled type 2 diabetes. It reflects the strength of our development and manufacturing capabilities and our commitment to delivering high‑quality medicines across global markets.”
-
Digvijay Singh, Regional Head – Brazil & LATAM:
“This approval marks an important step in strengthening our diabetes portfolio in Brazil. We look forward to working closely with our partner to make this treatment option available to patients and support better diabetes care across the country.”
Strategic Significance
- Portfolio expansion: Adds a high‑growth, innovative diabetes therapy to Sun Pharma’s global portfolio.
- Geographic diversification: Enhances Sun Pharma’s presence in the Latin American market, leveraging a local partner for rapid market entry.
- Revenue potential: Access to a sizable market (≈ USD 413 million) aligns with the company’s focus on innovative medicines, which currently represent about 22 % of total sales.
About Sun Pharmaceutical Industries Limited
Sun Pharma is a leading global pharmaceutical company with operations spanning Innovative Medicines, Generics, and Consumer Healthcare. It is the largest pharmaceutical firm in India and a major generic player in the United States and emerging markets. The company’s vertically integrated model supports manufacturing across five continents, serving patients in over 100 countries.
For more information, visit www.sunpharma.com and follow Sun Pharma on LinkedIn and X (formerly Twitter).
Contact for Investors & Media
- Dr. Abhishek Sharma – Tel: +91 22 4324 2929 – Email: abhi.sharma@sunpharma.com
- Gaurav Chugh – Tel: +91 22 4324 5373 – Email: gaurav.chugh@sunpharma.com
Sun Pharma's approval to launch semaglutide in Brazil is likely to give the stock a modest boost as investors price in a new high‑growth market, though the effect may be limited to the short term.
Sign in for impact outlook, horizons, comparables, and full intelligence analysis.
Forecast from comparable, historic events. Not investment advice.
Original Source Document
View the original exchange filing or announcement.
Frism Computing (OPC) Private Limited
#74, 15TH CROSS, JP Nagar III Phase, Bangalore South, Bangalore 560078, Karnataka